ANG.BO · BSE
ANG Lifesciences India Limited
₹39.49
+1.99% (+₹0.77)
Prev. close
₹38.72
Volume
2,984
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About ANG Lifesciences India Limited
ANG Lifesciences India Limited engages in manufacturing and sale of finished pharmaceutical formulations in India and internationally. Its product portfolio comprises therapeutics categories, such as antibiotics, antiviral, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, and beta lactamase inhibitor. The company also offers its finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, and lotions. ANG Lifesciences India Limited was incorporated in 2006 and is based in Amritsar, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Rajesh Gupta
Headquarters
Amritsar
Employees
379
Website
anglifesciences.comExchange
View on BSE ↗Key stats
Market cap
₹50.56 Cr
EPS (TTM)
₹-10.20
Beta (1Y · daily vs NIFTY 50)
0.25
Beta (5Y · monthly vs NIFTY 50)
1.29
Shares float
37.51 L
EPS · quarter ended Jun 2026
₹-3.25
Financial Performance
01 · Financials
The first plotted growth figure is computed against Mar 2022 revenue as filed with BSE; the two sources' revenue definitions differ by 0.1% on Mar 2023. FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹354.30 Cr | ₹219.78 Cr | ₹146.01 Cr | ₹92.54 Cr | ₹92.79 Cr | |
| EBITDA | ₹68.28 Cr | ₹23.17 Cr | ₹7.98 Cr | ₹-6.36 L | ₹1.25 Cr |
| ₹40.32 Cr | ₹-26.22 L | ₹-10.14 Cr | ₹-12.41 Cr | ₹-11.08 Cr | |
| Diluted EPS | — | ₹-0.2 | ₹-7.77 | ₹-9.51 | ₹-8.49 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹277.66 Cr | ₹242.44 Cr | ₹229.59 Cr | ₹208.95 Cr | |
| — | ₹70.75 Cr | ₹72.84 Cr | ₹83.21 Cr | ₹79.40 Cr | |
| Stockholders' equity | — | ₹86.22 Cr | ₹76.28 Cr | ₹63.98 Cr | ₹52.89 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹26.38 Cr | ₹-9.49 Cr | ₹-25.54 L | ₹11.03 Cr | |
| Investing cash flow | — | ₹-9.33 Cr | ₹19.89 Cr | ₹-1.59 Cr | ₹1.05 Cr |
| — | ₹-17.07 Cr | ₹-10.40 Cr | ₹1.68 Cr | ₹-11.74 Cr | |
| Capital expenditure | — | ₹-10.44 Cr | ₹-5.57 Cr | ₹-3.75 Cr | ₹-43.94 L |
| End cash position | — | ₹32.42 L | ₹31.85 L | ₹15.74 L | ₹49.40 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| ANG Lifesciences India Limited | ₹50.56 Cr | ₹38.72 | — | 0.96 | -21.0% | 1.50 | +0.3% | +7.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
ANG Lifesciences: FY26 Revenue ₹9,233 Cr, Loss ₹1,108 Cr
ANG Lifesciences India Limited reported a consolidated loss of ₹1,108.49 lakhs for the fiscal year ended March 31, 2026, on total income of ₹9,486.62 lakhs. The standalone net loss was ₹472.64 lakhs. The Pharmaceuticals segment generated most of the revenue but both segments reported losses.